Analysts forecast that aTyr Pharma, Inc. (NASDAQ:LIFE) will report $5.38 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for aTyr Pharma’s earnings. The highest sales estimate is $10.00 million and the lowest is $750,000.00. aTyr Pharma posted sales of $8.07 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 33.3%. The business is expected to report its next quarterly earnings report on Tuesday, May 11th.
According to Zacks, analysts expect that aTyr Pharma will report full year sales of $7.67 million for the current financial year, with estimates ranging from $3.00 million to $10.00 million. For the next year, analysts anticipate that the firm will post sales of $16.70 million, with estimates ranging from $2.30 million to $31.11 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that that provide coverage for aTyr Pharma.
aTyr Pharma (NASDAQ:LIFE) last posted its earnings results on Monday, March 22nd. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.35. aTyr Pharma had a negative net margin of 202.02% and a negative return on equity of 52.75%.
Shares of LIFE stock opened at $3.94 on Wednesday. aTyr Pharma has a 12-month low of $2.93 and a 12-month high of $8.33. The company has a market capitalization of $63.08 million, a PE ratio of -1.48 and a beta of 2.17. The firm has a 50 day moving average price of $4.43 and a two-hundred day moving average price of $4.22.
A number of institutional investors have recently bought and sold shares of the business. Alyeska Investment Group L.P. lifted its position in shares of aTyr Pharma by 11.9% during the 4th quarter. Alyeska Investment Group L.P. now owns 842,554 shares of the biotechnology company’s stock valued at $3,269,000 after acquiring an additional 89,908 shares during the period. Ikarian Capital LLC bought a new position in shares of aTyr Pharma in the fourth quarter worth $1,552,000. Finally, Virtu Financial LLC bought a new stake in aTyr Pharma during the fourth quarter worth about $108,000. Hedge funds and other institutional investors own 55.82% of the company’s stock.
About aTyr Pharma
aTyr Pharma, Inc develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. It operates in a single accounting segment.
Read More: How a Put Option Works
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.